SINGAPORE--(BUSINESS WIRE)--Sengenics, the Functional Proteomics Company, announced today that it has entered into a research collaboration agreement with GlaxoSmithKline (GSK). The collaboration will combine Sengenics’ functional proteomics capabilities with GSK’s scientific expertise in immunology, especially in drug discovery.
The collaboration will leverage Sengenics’ proprietary KREX™ technology to validate novel autoantibody biomarkers in patients with autoimmune diseases. These biomarkers were identified using the IMMUNOME™ protein array, a KREX™-based array with functionally validated, full-length, correctly folded proteins.
Andrew Jackson, Global Business Unit Director – Pharma, Sengenics said, “We are very pleased to enter into this exciting research collaboration with GSK. We hope to be able to determine the diagnostic and therapeutic potential for certain immune-mediated diseases, since they are characterised by the presence of autoantibodies.”
Sengenics is a Functional Proteomics company that leverages its patented KREX™ technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.